SCHEMBL30420677

C[C@@H](O)[C@H](NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCCCC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(=N)N)[C@@H](C)O)C(=O)NCCCC[C@H](NC(=O)[C@H](CCCCNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(=N)N)[C@@H](C)O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(=N)N)[C@@H](C)O)C(=O)NCC(=O)O

nearest known ligand 0.66

Predicted protein targets (top 8)

	gene	UniProt	supporting neighbours	confidence
▸	NPY4R	P50391	16/20	0.66

▸	NPY1R	P25929	10/20	0.66

▸	NPY5R	Q15761	8/20	0.66

▸	NPY2R	P49146	6/20	0.66

▸	OPRM1	P35372	1/20	0.52

▸	OPRD1	P41143	1/20	0.52

▸	OPRK1	P41145	1/20	0.52

▸	KISS1R	Q969F8	2/20	0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30974010	0.88	NPY4R (0.72)	NPY4RNPY1RNPY5RNPY2ROPRM1
SCHEMBL31031552	0.88	KISS1R (0.59)	NPY4RNPY1RNPY5RNPY2ROPRM1
SCHEMBL7594012	0.87	NPY4R (0.66)	NPY4RNPY1RNPY5RNPY2ROPRM1
SCHEMBL7594031	0.87	NPY4R (0.66)	NPY4RNPY1RNPY5RNPY2ROPRM1
SCHEMBL29732346	0.87	NPY4R (0.66)	NPY4RNPY1RNPY5RNPY2ROPRM1
SCHEMBL30006452	0.87	NPY4R (0.67)	NPY4RNPY1RNPY5RNPY2RKISS1R
SCHEMBL31345750	0.86	NPY4R (0.64)	NPY4RNPY1RNPY5RNPY2ROPRM1
SCHEMBL31680260	0.86	NPY4R (0.69)	NPY4RNPY1RNPY5RNPY2ROPRM1
SCHEMBL30852308	0.86	NPY4R (0.69)	NPY4RNPY1RNPY5RNPY2ROPRM1
SCHEMBL30690149	0.86	NPY4R (0.59)	NPY4RNPY1RNPY5RNPY2ROPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20230256019-A1	METHOD FOR STABILIZING BINDING OF NK CELL AND ANTIBODY, AND USE THEREOF	GAIA BIOMEDICINE INC. (JP)	2023-08-17	—	—	US	disclosed
EP-4173640-A1	METHOD FOR STABILIZING BINDING OF ANTIBODY TO NK CELL AND USE THEREOF	GAIA BioMedicine Inc. (JP)	2023-05-03	—	—	EP	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20230256019-A1	METHOD FOR STABILIZING BINDING OF NK CELL AND ANTIBODY, AND USE THEREOF	LY96, KLRK1, CD47	NPY4R 4309/4885NPY1R 4378/4885NPY5R 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.